AI in Clinical Trials Market Size to Attain USD 18.82 Bn by 2033

The global AI in clinical trials market size was estimated to be around US$ 1.6 billion in 2023 and is projected to reach US$ 18.82 billion by 2033, indicating a CAGR of 28% from 2024 to 2033.

Key Takeaways

• North America held the dominating share of the AI in clinical trials market in 2023.
• By offering, the services segment held the largest market share in 2023.
• By technology, the deep learning segment held the dominating market share in 2023.
• By application, the infectious disease segment dominated the market in 2023.
• By end-user, the pharmaceutical segment held the largest share of the market in 2023; the segment is observed to sustain dominance throughout the forecast period.

The AI in Clinical Trials market is experiencing a transformative surge as artificial intelligence (AI) technologies revolutionize the landscape of clinical research and development. This sector harnesses the power of advanced algorithms, machine learning, and data analytics to enhance efficiency, accuracy, and speed in various stages of clinical trials. The integration of AI not only optimizes the trial process but also opens up new possibilities for precision medicine, ultimately improving patient outcomes.

Get a Sample: https://www.precedenceresearch.com/sample/3743

Growth Factors:

The rapid growth of the AI in Clinical Trials market can be attributed to several key factors. Firstly, the increasing complexity of clinical trials demands advanced technologies to handle vast datasets and streamline decision-making processes. AI facilitates predictive analytics, enabling more informed trial designs and patient stratification. Additionally, the rising prevalence of chronic diseases and the subsequent demand for innovative therapies have accelerated the adoption of AI, as it expedites drug discovery and development

AI in Clinical Trials Market Scope

Read More: Network Engineering Services Market Size Will be $97 Bn by 2033

Opportunities

Numerous opportunities abound in the AI in Clinical Trials market. The ability of AI to enhance patient recruitment, optimize trial protocols, and predict patient responses provides a significant advantage. The integration of AI-powered tools for real-time monitoring and data analysis opens avenues for adaptive trial designs, leading to more agile and cost-effective clinical studies. Collaborations between pharmaceutical companies and AI developers present further opportunities to leverage cutting-edge technologies for improved trial outcomes.

Challenges

Despite its potential, the AI in Clinical Trials market faces challenges that need to be addressed for sustainable growth. Interoperability issues between different AI platforms, data security concerns, and the need for regulatory clarity pose significant hurdles. Additionally, the reluctance of traditional stakeholders to embrace AI, coupled with the requirement for substantial investments in infrastructure and skilled personnel, presents obstacles that must be overcome to fully unlock the potential of AI in clinical trials.

Reasons to Purchase this Report:

• Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
• In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
• Market size in USD million and volume in million units provided for each segment and sub-segment.
• Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
• Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

AI in Clinical Trials Market Companies

• AiCure
• Antidote Technologies
• Deep 6 AI
• Mendel.ai
• Phesi
• Saama Technologies
• Signant Health
• Trials.ai
• Innoplexus
• IQVIA
• Median Technologies
• Medidata

Segments Covered in the Report

By Offering

• Software
• Services

By Technology

• Machine learning
• Deep learning
• Supervised

By Application

• Cardiovascular
• Metabolic
• Oncology
• Infectious diseases

By End-user

• Pharma
• Biotech
• CROs

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on AI in Clinical Trials Market 

5.1. COVID-19 Landscape: AI in Clinical Trials Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global AI in Clinical Trials Market, By Offering

8.1. AI in Clinical Trials Market, by Offering, 2024-2033

8.1.1. Software

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Services

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global AI in Clinical Trials Market, By Technology

9.1. AI in Clinical Trials Market, by Technology, 2024-2033

9.1.1. Machine learning

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Deep learning

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Supervised

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global AI in Clinical Trials Market, By Application 

10.1. AI in Clinical Trials Market, by Application, 2024-2033

10.1.1. Cardiovascular

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Metabolic

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Oncology

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Infectious diseases

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global AI in Clinical Trials Market, By End-user 

11.1. AI in Clinical Trials Market, by End-user, 2024-2033

11.1.1. Pharma

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Biotech

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. CROs

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global AI in Clinical Trials Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Offering (2021-2033)

12.1.2. Market Revenue and Forecast, by Technology (2021-2033)

12.1.3. Market Revenue and Forecast, by Application (2021-2033)

12.1.4. Market Revenue and Forecast, by End-user (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Offering (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Technology (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Application (2021-2033)

12.1.5.4. Market Revenue and Forecast, by End-user (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Offering (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Technology (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Application (2021-2033)

12.1.6.4. Market Revenue and Forecast, by End-user (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Offering (2021-2033)

12.2.2. Market Revenue and Forecast, by Technology (2021-2033)

12.2.3. Market Revenue and Forecast, by Application (2021-2033)

12.2.4. Market Revenue and Forecast, by End-user (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Offering (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Technology (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Application (2021-2033)

12.2.5.4. Market Revenue and Forecast, by End-user (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Offering (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Technology (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Application (2021-2033)

12.2.6.4. Market Revenue and Forecast, by End-user (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Offering (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Technology (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Application (2021-2033)

12.2.7.4. Market Revenue and Forecast, by End-user (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Offering (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Technology (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Application (2021-2033)

12.2.8.4. Market Revenue and Forecast, by End-user (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Offering (2021-2033)

12.3.2. Market Revenue and Forecast, by Technology (2021-2033)

12.3.3. Market Revenue and Forecast, by Application (2021-2033)

12.3.4. Market Revenue and Forecast, by End-user (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Offering (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Technology (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Application (2021-2033)

12.3.5.4. Market Revenue and Forecast, by End-user (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Offering (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Technology (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Application (2021-2033)

12.3.6.4. Market Revenue and Forecast, by End-user (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Offering (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Technology (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Application (2021-2033)

12.3.7.4. Market Revenue and Forecast, by End-user (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Offering (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Technology (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Application (2021-2033)

12.3.8.4. Market Revenue and Forecast, by End-user (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Offering (2021-2033)

12.4.2. Market Revenue and Forecast, by Technology (2021-2033)

12.4.3. Market Revenue and Forecast, by Application (2021-2033)

12.4.4. Market Revenue and Forecast, by End-user (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Offering (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Technology (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Application (2021-2033)

12.4.5.4. Market Revenue and Forecast, by End-user (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Offering (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Technology (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Application (2021-2033)

12.4.6.4. Market Revenue and Forecast, by End-user (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Offering (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Technology (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Application (2021-2033)

12.4.7.4. Market Revenue and Forecast, by End-user (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Offering (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Technology (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Application (2021-2033)

12.4.8.4. Market Revenue and Forecast, by End-user (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Offering (2021-2033)

12.5.2. Market Revenue and Forecast, by Technology (2021-2033)

12.5.3. Market Revenue and Forecast, by Application (2021-2033)

12.5.4. Market Revenue and Forecast, by End-user (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Offering (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Technology (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Application (2021-2033)

12.5.5.4. Market Revenue and Forecast, by End-user (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Offering (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Technology (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Application (2021-2033)

12.5.6.4. Market Revenue and Forecast, by End-user (2021-2033)

Chapter 13. Company Profiles

13.1. AiCure

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Antidote Technologies

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Deep 6 AI

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Mendel.ai

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Phesi

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Saama Technologies

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Signant Health

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Trials.ai

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Innoplexus

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. IQVIA

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.autoindustrybulletin.com/